Tuesday August 14, 2018 0 comments
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately.
Cox has been appointed to the Audit and Corporate Governance Committees of the board. Kyle Lefkoff, general partner of Boulder Ventures Ltd., who has served as chair of Array's board since its inception, has stepped down but will continue to serve as a director.
Cox is an experienced corporate director with a distinguished career in the biopharmaceutical industry. She served as executive VP and president of Schering-Plough's global pharmaceutical business, which generated approximately $16 billion in annual sales.
Before joining Schering-Plough, Cox served as executive VP and president of Pharmacia's global prescription business, senior VP of Pharmacia & Upjohn's global prescription business, and as VP of women's healthcare at Wyeth-Ayerst.
"All of us at Array are grateful to Mr. Lefkoff for his dedication and service to the company and acknowledge his many important contributions as Array evolved to a fully-integrated, commercial-stage biopharmaceutical company,” said Ron Squarer, Array’s CEO.
“We look forward to his continued insight and guidance as a valued member of our board of directors. We are delighted to have Ms. Cox join and lead our board of directors. She brings a wealth of commercial expertise to Array that will help drive the success of our recent launch of BRAFTOVI + MEKTOVI."
"I am thrilled that BRAFTOVI + MEKTOVI are now available to patients and I look forward to continuing to work with the Array team," said outgoing Chair Lefkoff. "
“Ms. Cox is an experienced pharmaceutical executive with a highly successful history of commercial management. She is ideally suited to lead our board into the next phase of Array's growth and development, and we are proud to welcome her to the Array team."
"I am excited to join Array's board as the company commercializes its first FDA-approved products in metastatic melanoma with the approval of BRAFTOVI + MEKTOVI,” said Cox.
“Array also has an impressive drug discovery and development engine, and I look forward to working closely with the team and my fellow board members to advance innovative treatments that have the potential to significantly benefit patients in need."
Cox currently serves on the boards of Celgene, Cardinal Health, electroCore and Texas Instruments (previously as lead director). She also serves as the executive chair of the Humacyte, Inc., board of directors through 2018.
Most recently, Cox served as chair and CEO of Humacyte, Inc., which she joined in 2010. She also served as chair of Prism Pharmaceuticals, sold to Baxter Corporation in 2011. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility.
Cox has been named to FORTUNE Magazine's list of the "50 Most Powerful Women in Business" six times. Her work has been featured in Harvard Business Review and in the New York Times bestseller, The Profit Zone, and she is a graduate of the Massachusetts College of Pharmacy.